Recent Company News

• 10:55 PM ET Jun 17, 2026
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 07:05 AM ET Jun 16, 2026
  

  Zai Lab receives EMA Orphan Drug Designation for zocilurtatug pelitecan (Zoci) in pulmonary neuroendocrine carcinomas ($17.73, 0.00)

• 09:03 PM ET Jun 10, 2026
  

  NICE recommends Genmab's Tivdak to treat recurrent or metastatic cervical cancer that has progressed on or after systemic treatment (DKK 1608.00, 0.00)

• 08:39 PM ET Jun 08, 2026
  

  Zai Lab's TIVDAK obtains China NMPA approval for recurrent/metastatic cervical cancer ($16.48, 0.00)

• 01:05 AM ET Jun 03, 2026
  

  argenx presents new data on VYVGART at EULAR 2026 ($802.17, 0.00)

• 08:59 AM ET May 22, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 09:18 PM ET May 22, 2026
  

  StreetAccount Sector Summary - Healthcare Weekly Recap

• 09:22 AM ET May 22, 2026
  

  StreetAccount Summary - US Pre-market trading update

• 06:40 PM ET May 21, 2026
  

  CORRECTION: ZAI Lab President and COO Josh Smiley to leave company, effective 22-May ($19.10, 0.00)